Biosimilars Forum Applauds Organon and Samsung Bioepis for Launch of HADLIMA™
Juliana M. Reed, executive director the Biosimilars Forum, released the following statement commending Organon and Samsung Bioepis for launching HADLIMA™ (adalimumab-bwwd). This launch contributes to a crucial wave of Humira® (adalimumab) biosimilars launching in the U.S. this year. These FDA-approved therapies could save the U.S. healthcare system billions of dollars per year – if patients can access these lower-cost treatments.
“Biosimilars are an essential part of the American healthcare system. The introduction of HADLIMA™ by Organon and Samsung Bioepis represents another Humira® (adalimumab) biosimilar that can foster a more competitive prescription drug marketplace, resulting in a substantial reduction in costs to the healthcare system.
“The cost-savings potential of biosimilars can only be realized if these treatments are accessible to the providers and patients that need them. These safe and effective treatments must be included on formularies, enabling the biosimilars market to function as intended and lower prescription drug expenses for millions of Americans.
Humira® is the most expensive prescription drug in the United States and can cost patients upwards of $84,000 per year. It has experienced more than a 470% price increase since first introduced on the market.
“This is why the Biosimilars Forum calls on the Biden Administration, Congress, and federal regulators to recognize this pivotal moment and ensure that Humira biosimilars are accessible to all patients, including Medicare patients. If biosimilar competition had been available, Medicare could have saved an estimated $2.19 billion on Humira® over the course of four years.
“The biosimilars industry needs unwavering support from policymakers and stakeholders to provide patients with the lower-cost alternatives they deserve. I eagerly anticipate collaborating with lawmakers from both sides of the aisle as additional Humira® (adalimumab) biosimilarsare introduced, delivering long-awaited and more affordable options for the world’s top-selling drug.”
For more information on the Biosimilars Forum’s work to increase access to lower-cost biosimilars, visit biosimilarsforum.org.